Chinese Herb for the Treatment of Depression and Anxiety Disorders

• Status: Unknown status
• Trial end date: 2018-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Anxiety and depression are currently among the ten most important public health concerns, and in recent years, have reached epidemic proportions. Anxiety is recognized as the main risk factor for many diseases including cardiovascular, metabolic and neuropsychiatric disorders. Current anxiolytic medications have a relatively low success rate (~50%) and are associated with many deleterious side-effects. The investigators aim to investigate the efficacy, safety, and tolerability of a novel herbal treatment on anxiety and depression symptoms in a 6-week double-blind randomized trial.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mazra Mental Health Center
• Collaborator: The Academic College of Tel-Aviv Yaffo
• Treatments: Citalopram; Dexetimide; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• Patients of both sexes suffering from mild to moderate depressive episode of major depressive disorder (MDD) according to Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-V.

• Subjects of both sexes meeting the DSM-V criteria for dysthymia.

• Patients of both sexes meeting the DSM-V criteria for Generalized Anxiety Disorder (GAD), Panic Disorder and Social Anxiety Disorder, Adjustment disorder.

• Age 18-65.

• Not receiving antidepressant drugs.

• Hamilton Depression Rating Scale (HAM-D) scores are ≥8 and ≤ 18.

• Hamilton Anxiety Rating Scale (HAM-A) scores ≥17 and ≤ 30.

Exclusion Criteria:

• Current active and persistent substance and/or alcohol abuse.

• Mental retardation

• Other major psychiatric disorders: Psychosis, Severe MDD and Bipolar disorder

• Suicide ideation

• Pregnancy

• Systolic Blood Pressure < 100 mm Hg

• Heart rate < 60 times/min

• Patient with medical history of cardiac palpitation and other cardiac diseases